The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with alzheimer disease: A randomized controlled trial

Archives of Internal Medicine

Volumn 165, Issue 15, 2005, Pages 1737-1742

  Sato, Yoshihiro ^a   Kanoko, Tomohiro ^b   Satoh, Kei ^b   Iwamoto, Jun ^c  

^a Mitate Hospital   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ERGOCALCIFEROL; RISEDRONIC ACID;

ABDOMINAL PAIN; AGED; ALZHEIMER DISEASE; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESOPHAGITIS; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HUMAN; HYPERPARATHYROIDISM; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY;

ACCIDENTAL FALLS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CALCIUM CHANNEL BLOCKERS; COMORBIDITY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ERGOCALCIFEROLS; ETIDRONIC ACID; FEMALE; HIP FRACTURES; HUMANS;

EID: 23744507892     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.15.1737     Document Type: Article

References (28)

1. Johansson C, Skoog I. A population-based study on the association between dementia and hip fractures in 85-year olds. Aging (Milano). 1996;8:189-196.
2. Melton LJ III, Beard CM, Kokmen E, Atkinson EJ, O'Fallon WM. Fracture risk in patients with Alzheimer's disease. J Am Geriatr Soc. 1994;42:614-619.
3. van Staa TP, Leufkens HG, Cooper C. Utility of medical and drug history in fracture risk prediction among men and women. Bone. 2002;31:508-514.
4. Buchner DM, Larson EB. Falls and fractures in patients with Alzheimer-type dementia. JAMA. 1987;257:1492-1495.
5. Nurmi I, Narinen A, Luthje P, Tanninen S. Cost analysis of hip fracture treatment among the elderly for the public health services: a 1-year prospective study in 106 consecutive patients. Arch Orthop Trauma Surg. 2003;123:551-554.
6. Holmes J, House A. Psychiatric illness predicts poor outcome after surgery for hip fracture: a prospective cohort study. Psychol Med. 2000;30:921-929.
7. Matsueda M, Ishii Y. The relationship between dementia score and ambulatory level after hip fracture in the elderly. Am J Orthop. 2000;29:691-693.
8. Morrison RS, Siu AL. Mortality from pneumonia and hip fractures in patients with advanced dementia. JAMA. 2000;284:2447-2448.
9. Nightingale S, Holmes J, Mason J, House A. Psychiatric illness and mortality after hip fracture. Lancet. 2001;357:1264-1265.
10. Sato Y, Asoh T, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer's disease. Bone. 1998;23:555-557.
11. Sato Y, Kanoko T, Satoh K, Iwamoto J. Risk factors for hip fracture among elderly patients with Alzheimer's disease. J Neurol Sci. 2004;223:107-112.
12. Kipen E, Helme RD, Wark JD, Flicker L. Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia. J Am Geriatr Soc. 1995;43:1088-1091.
13. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CW, Papapoulos SE. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone. 2003;33:805-811.
14. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83-91.
15. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333-340.
16. Fukunaga M, Kushida K, Kishimoto H, et al. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int. 2002;13:971-979.
17. Cranney A, Waldegger L, Zytaruk N, et al. Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database Syst Rev. 2003;4:CD004523.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Standian EM. Clinical diagnosis of Alzheimer's disease: report on the NINCDS-ADRADA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-944.
19. Folstein MF, Folstein SF, McHugh PR. "Mini Mental State:" a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
20. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med J. 1965;14:61-65.
21. Komar L, Nieves J, Cosman F, Rubin A, Shen V, Lindsay R. Calcium homeostasis of an elderly population upon admission to a nursing home. J Am Geriatr Soc. 1993;41:1057-1064.
22. Matsumoto C, Kushida K, Yamazaki K, Imose K, Inoue T. Metacarpal bone mass in normal and osteoporotic Japanese women using computed X-ray densitometry. Calcif Tissue Int. 1994;55:324-329.
23. Sato Y, Asoh T, Kaji M, Oizumi K. Benefical effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke. J Bone Miner Res. 2000;15:2487-2494.
24. Sato Y, Kaji M, Tsuru T, Oizumi K. Risk factors for hip fracture among elderly patients with Parkinson's disease. J Neurol Sci. 2001;182:89-93.
25. Sato Y, Kanoko T, Yasuda H, Satoh K, Iwamoto J. Beneficial effect of etidronate therapy in immobilized hip fracture patients. Am J Phys Med Rehabil. 2004;83:298-303.
26. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA. 2004;291:1999-2006.
27. Ramnemark A, Nyberg L, Borssén B, Olsson T, Gustafson Y. Fractures after stroke. Osteoporos Int. 1998;8:92-95.
28. Burns A, Marsh A, Bender DA. Dietary intake and clinical, anthropometric and biochemical indices of malnutrition in elderly demented patients and non-demented subjects. Psychol Med. 1989;19:383-391.